BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//KO
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA 일정 캘린더
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-90@catalystbrief.girapphe.com
DTSTAMP:20261117T061557Z
LAST-MODIFIED:20261117T061557Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:임상 결과: Jiangsu HengRui Medicine Co.\, Ltd. — SHR-A1811 [2
 026년 12월 중]
DESCRIPTION:임상 3상 1차 종료 예정 (HER2-Positive\, Unresectable an
 d/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab
  and Taxane). 결과 발표는 이후가 될 수 있습니다.\n출처: ht
 tps://clinicaltrials.gov/study/NCT05424835\nhttps://catalystbrief.girapphe
 .com/e/90?lang=ko\n투자 조언이 아닙니다. 일정은 변경될 수 
 있습니다.
URL:https://catalystbrief.girapphe.com/e/90?lang=ko
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
